Biopharmaceutical New Technologies (BioNTech) announced on Wednesday that the COVID-19 vaccine that they co-developed with Pfizer triggered a strong immune response in the early stage of human trials.
Additional takeaways
“Planning to test most promising of four vaccines on up to 30,000 healthy participants in the US and Europe.”
“Planning to manufacture up to 100 million doses by the end of 2020 if regulators give the green light.”
“Will also make at least another 1.2 billion doses by the end of 2021 in Germany and the US.”
Market reaction
This headline seems to be providing a boost to market sentiment and helping major European equity indexes recover from daily lows. As of writing, Germany’s DAX 30 was down 0.42% on the day at 12,260 points.
Share
